Merck, Inc.
🇵🇭Philippines
COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)
Phase 2
Completed
- Conditions
- Glaucoma
- Interventions
- Drug: timolol/dorzolamide combination
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00832377
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00833053
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00832390
The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00832624
ALPHA Sitagliptin Add on to Metformin (0431-103)
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 608
- Registration Number
- NCT00833027
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
Phase 2
Completed
- Conditions
- Metastases of Central Nervous SystemMelanomaBreast NeoplasmCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 162
- Registration Number
- NCT00831545
The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)
Phase 3
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: PlaceboDrug: Diquafosol tetrasodium ophthalmic solution, 2%
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 490
- Registration Number
- NCT00831662
A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)
Phase 1
Terminated
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: MK-0941 5 mgDrug: MK-0941 20 mg
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00830791
A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00830076
A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: MK-8998
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00827918
© Copyright 2025. All Rights Reserved by MedPath